Patients often ask one question before trying shockwave therapy.
“Is it safe?”
Your answer should be confident, honest, and specific. High-intensity focused extracorporeal shockwave therapy, or focused ESWT, offers a non-invasive, drug-free, injection-free treatment option with no surgery and no routine downtime. However, safe treatment requires proper screening, accurate targeting, appropriate settings, and clear communication before the first session.
When your patients understand what will happen, they feel more prepared. They also tend to tolerate the protocol better, miss fewer sessions, and complete their recommended care plans.
Safe Screening. Clear Expectations. Better Care.
JointWave™ delivers powerful acoustic energy into targeted soft tissue, joints, and tendons. The mechanical stimulus supports the body’s natural healing response and may help improve circulation, reduce inflammation, and support tissue regeneration.
The treatment does not involve an incision, medication, injection, or surgical recovery period. Most patients remain awake, communicate throughout the session, and leave the office under their own power.
A 2026 narrative review on extracorporeal shock wave therapy for pain management in musculoskeletal rehabilitation by Gao and Zhao in the Journal of International Medical Research describes a generally favourable safety profile, with most adverse events being mild and transient local reactions, when clinicians use appropriate protocols. The safety profile depends on more than the device itself. It also depends on proper diagnosis, treatment selection, patient positioning, energy control, and documentation.
Your team should treat every session as a clinical procedure, not simply as a device application.
✅ Confirm the diagnosis and treatment objective.
✅ Review medical history, medications, implants, and recent procedures.
✅ Screen the treatment area for infection, malignancy, open wounds, and other local concerns.
✅ Explain expected sensations and possible short-term reactions.
✅ Document the treatment site, applicator, settings, patient feedback, and response.
JointWave treatment heads add another practical advantage. They feature a technologically superior design built for high-volume clinical use and are engineered for durability that supports consistent treatment delivery and long-term practice planning.
Deep Tapping. Mild Discomfort. Short Recovery.
Patients want to know what shockwave therapy feels like before they agree to treatment. Avoid vague language. Explain the experience in plain terms.
Most patients describe the sensation as deep tapping, pressure, or a rapid pulse over the target area. The feeling can become more noticeable over sensitive tissue or directly over a painful structure. Mild discomfort may occur during the session, but it generally fades as the applicator moves across the treatment area.
The clinician can adjust the treatment based on patient feedback and the selected protocol. Your patient should know that they can communicate at any point. The treatment should not become a test of endurance.
After treatment, patients may notice:
✅ Temporary soreness that feels similar to post-exercise muscle soreness.
✅ Mild redness or warmth in the treated area.
✅ Temporary tenderness or aching.
✅ Occasional swelling or sensitivity.
✅ Mild bruising in a small number of patients.
These effects usually settle within approximately 24 to 48 hours. Patients should follow your office’s aftercare instructions and avoid activities that your clinical protocol restricts.
Set the right expectation. JointWave treatment does not guarantee an immediate change in symptoms, and results vary by condition, tissue status, chronicity, diagnosis, and adherence to the complete care plan.
Screen First. Treat Precisely. Document Everything.
Before session one, use a consistent screening process. A written checklist helps your chiropractor and trained clinical assistants ask the same questions every time.
Do not treat without appropriate clearance
High-intensity focused ESWT requires particular caution in patients with:
Pregnancy or possible pregnancy.
Significant bleeding disorders or coagulopathy.
Current anticoagulant therapy or a high medication-related bleeding risk.
Active infection in or near the treatment area.
Known or suspected malignancy in the treatment field.
Open growth plates in pediatric patients when the growth plate would fall within the treatment field.
A cardiac pacemaker, defibrillator, or leads near the treatment zone.
Metal implants near the treatment zone.
A joint prosthesis in or near the intended treatment field.
Recent corticosteroid injection or known tendon compromise near the target area.
For patients with coagulopathy, significant anticoagulation, or a joint prosthesis, do not proceed without physician clearance and a documented clinical decision.
Avoid vulnerable structures
High-intensity focused acoustic energy should not be directed over or through structures that require special protection.
Do not target:
Lung tissue or apical tissue.
The brain or spinal cord.
The spine itself.
Major nerves.
Major blood vessels.
An active infection or local tumor.
An open growth plate.
The beam path matters. A treatment site may appear superficial while the intended focal zone reaches deeper tissue. Your clinician must consider anatomy, positioning, tissue depth, and the selected applicator before activating the system.
A patient with an implant or cardiac device may still require an individualized evaluation. Your office should follow the device instructions for use, applicable laws, and physician judgment. When uncertainty exists, pause treatment and obtain clearance.
Explain Risk. Build Trust. Improve Follow-Through.
An honest safety conversation does more than reduce anxiety. It improves the patient experience.
Patients who understand the tapping sensation are less likely to interpret normal treatment discomfort as a warning sign. Patients who know that mild soreness or redness may occur are less likely to feel surprised afterward. Patients who understand that results vary are more likely to follow the full plan instead of judging the treatment after one session.
That makes safety education a practical part of patient retention and care-plan completion.
The conversation should never sound like a guarantee. It should sound like professional guidance.
A patient-facing script for your team
“JointWave uses focused acoustic energy to stimulate the tissue we are treating. It does not involve medication, an injection, or surgery. During the session, you may feel deep tapping or pressure. Some areas can feel mildly uncomfortable, but we can adjust the treatment based on your feedback.
“Afterward, you may notice temporary soreness, redness, or tenderness. A small number of patients develop mild bruising. These effects usually improve within a day or two. Please contact us if you experience severe or worsening pain, significant swelling, increasing bruising, new weakness or numbness, fever, or any symptom that concerns you.
“Results vary by condition and by patient. We will monitor your response and adjust your care plan when appropriate. Before we begin, please tell us about pregnancy or possible pregnancy, blood thinners, bleeding disorders, infections, cancer near the treatment area, implants, a pacemaker or defibrillator, recent steroid injections, or any other medical concern.”
Train every team member to use consistent language. A trained clinical assistant can support education and documentation within your office’s scope of practice. The treating clinician remains responsible for diagnosis, treatment selection, contraindication review, and clinical oversight.
Install Confidently. Train Thoroughly. Standardize Care.
Adding shockwave therapy should not require your team to build a safety process from scratch.
JointWave supports implementation with:
✅ In-office installation assistance.
✅ Staff training for safe system operation and patient communication.
✅ A written protocol library to support consistent screening and documentation.
✅ Marketing materials that help your team explain the service accurately.
✅ Durable treatment heads built for high-volume clinical use.
A written protocol should define who completes the screening, where the answers are documented, when physician clearance is required, how treatment settings are recorded, and which post-treatment instructions the patient receives.
This structure protects the patient experience and helps your practice deliver a more consistent service. It also gives your team a clear process for introducing a non-invasive, cash-based care option without relying on improvised explanations.
Better Screening. Better Conversations. Better Care.
JointWave shockwave therapy has a strong safety profile when qualified clinicians select appropriate patients, respect contraindications, protect vulnerable anatomy, and monitor patient feedback.
The standard is not to promise that treatment will feel like nothing. The standard is to explain what patients may feel, identify when treatment should not proceed, and give patients clear instructions for what comes next.
Use the same approach in your clinic.
Screen carefully. Explain honestly. Treat precisely.
If you want to see how JointWave fits into your practice, request a risk-free 30-day in-office trial with no obligation. Your team can experience the system, review the workflow, educate patients, and decide based on real clinical use.
Request your risk-free 30-day JointWave™ in-office trial
This article provides general educational information and does not replace professional medical judgment, applicable regulations, manufacturer instructions for use, or physician clearance. Always follow your jurisdiction’s requirements and the JointWave clinical documentation and safety protocols.